Search

VIENNA—Understanding the emerging genomic landscape of breast cancer needed international research including large molecular screening projects—according to Peter Campbell MD PhD, head of Cancer Genet

VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Confer

VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from th

VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Bre

VIENNA—Estrogen receptor negative breast cancer might be prevented by strategies under investigation including HER2-targeting, vaccination and treatment with metformin or retinoids. Powel Brown MD, Ch

VIENNA—Latest research on breast cancer prevention was reported at the 20125 St Gallen breast cancer conference in a session concluded by Jack Cuzick, PhD, Director of the Wolfson Institute of Prevent

ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch

SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powle

SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific su

SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2